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Drug resistance plays an important role in chemotherapy
failure in breast cancer. We studied the expression of MDR1,
MRP, LRP, DNA topoisomerases, p53 and Ki-67 in different
groups of breast cancer patients in relation to chemotherapy.
Tissues from 6 normal breasts and 20 primary operable, 40
locally advanced and 10 anthracycline-resistant metastatic
breast cancers were assessed. Sequential samples of the same
patient were available from 17 patients with locally advanced
breast cancer undergoing neo-adjuvant chemotherapy and in
7 metastatic patients undergoing paclitaxel treatment. Pro-
tein expression was investigated by immunohistochemistry.
Significantly higher protein expression was observed for Pgp,
Ki-67 and p53 in the locally advanced breast cancers than in
primary operable breast cancers. No other significant differ-
ences in protein expression were found among the 3 breast
cancer groups. Expression of none of the markers that could
be assessed (Pgp, MRP, LRP, p53 and Ki-67) in locally ad-
vanced breast cancer had predictive value for pathological
response. Interestingly, after chemotherapy a significant de-
crease in percentage of Ki-67 positive tumor cells was ob-
served, whereas the other markers did not vary substantially.
Furthermore, considering all breast cancer samples, a cumu-
lative dose of doxorubicin G400 mg/m2 inversely correlated
with Ki-67 positivity. However, 2 patients with a pathological
complete remission had only 5–10% Ki67-positive tumor cells
before chemotherapy, indicating that Ki67 negativity itself is
not responsible for chemoresistance. In conclusion, none of
the known proteins related to multidrug resistance predicted
response to chemotherapy in breast cancer, and resistant
clones left behind generally had a low proliferation rate. Int. J.
Cancer 71:787–795, 1997.
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Breast cancer is the most common malignancy among women in
the Western world (Harris et al., 1993). Chemotherapy represents a
major treatment modality of various stages of this disease. Despite
radical surgery, approximately 50% of resected patients eventually
relapse. In these patients adjuvant systemic treatment (chemother-
apy and hormone therapy) prolongs long-term survival (Early
Breast Cancer Trialists’ Collaborative Group, 1992); nevertheless,
35% of patients die from the disease. When surgery is not feasible
or is too mutilating, such as in locally advanced breast cancer,
neo-adjuvant chemotherapy can achieve high remission rates
(70–90% clinical response rate) and allow adequate local control
afterwards (generally surgery followed by radiation); the 5-year
survival for stage IIIB patients remains, however, below 50%
(Harris et al., 1993). For patients who develop distant metastases,
first-line combination chemotherapy is generally effective, with a
50–70% response rate (Porrka et al., 1994). Response rates decline
to 20–30% in second-line chemotherapy, and all metastatic patients
eventually die from resistant disease.
The presence ab initio or the development of cell clones which
are resistant to drugs is thought to be responsible for the failure of
chemotherapy. Little is known about the causes of drug resistance
in breast cancer. Most available studies investigated the role of Pgp
in this disease. A correlation has been observed between Pgp
expression in breast cancer cells obtained from patients and in vitro
resistance to doxorubicin (Sanfilippo et al., 1991; Keith et al.,
1990; Salmon et al., 1989). Furthermore, high Pgp expression in 17
locally advanced breast cancer patients was associated with the
lack of response to neo-adjuvant chemotherapy (doxorubicin,
vincristine, cyclophosphamide and 5-fluorouracil) and a shorter
disease-free survival (Verelle et al., 1991).
Pgp acts as an energy-dependent drug efflux pump (van Kalken
et al., 1991), and belongs to the ATP-binding cassette transporter
superfamily, like the more recently identified MRP (Cole et al.,
1992). Like Pgp, MRP can also function as a plasma membrane
drug-efflux pump (Zaman et al., 1994), and its overexpression has
been associated with increased ATP-dependent glutathione S-
conjugate transport (Mu¨ller et al., 1994). Patterns of cross-
resistance in vitro vary slightly between Pgp andMRPoverexpress-
ing cells, and interestingly, paclitaxel does not appear to be a
substrate for MRP (Zaman et al., 1994; Mu¨ller et al., 1994).
Other mechanisms have been found to cause similar multidrug
resistance patterns in cancer cell lines. In several resistant cell lines
selected by exposure to MDR drugs, the overexpression of a new
protein has been discovered, which is independent of Pgp expres-
sion. This protein has been called LRP (lung resistance protein),
originally indentified in a lung cancer multidrug-resistant line
(Scheper et al., 1993). The LRP gene maps proximal to the MRP
gene on the short arm of chromosome 16, and its product has been
demonstrated to be the major human vault protein (Scheffer et al.,
1995). Given the cellular localization of the vaults in multi-subunit
organelles, associated with cytoplasmic vesicle structures and
nuclear pore complexes, a function in nucleo-cytoplasmic transport
of a wide variety of substrates has been suggested (Scheffer et al.,
1995).
DNA topoisomerase II, being the target of anthracyclines and
epipodophyllotoxins, can also be involved in causing MDR:
decreased topo IIa expression, decreased activity or an altered
function of the enzyme can lead to a MDR multidrug-resistant
phenotype in vitro, that is distinct from the classical MDR
phenotype (Giaccone, 1994).
It has been suggested that mutant p53 may be responsible for
broad resistance to cytotoxic drugs, as wild-type p53 is required for
the efficient activation of apoptosis following treatment with
anticancer drugs (Lowe et al., 1993, 1994). The p53 tumor
suppressor gene regulates genomic stability (Greenblatt et al.,
1994), and inactivation of its product by several mechanisms,
including point mutation, gene deletion, sequestration by mdm-2
and binding to proteins encoded by DNA tumor viruses, is at
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present the most common event identified in human cancers. In
breast cancer, p53 is often mutated (Greenblatt et al., 1994).
Our study was undertaken to investigate the expression of 8
proteins, a number of which are involved in broad resistance to
drugs, in different groups of patients with breast cancer. In
particular, we compared protein expression levels in sequential
samples of locally advanced breast cancer patients undergoing
neo-adjuvant chemotherapy, and in serial biopsies of anthracycline-
resistant, metastatic breast cancer patients undergoing chemother-
apy with paclitaxel.
MATERIAL AND METHODS
Patient material
Normal breast tissue and tumors from 3 groups of breast cancer
patients were used in our study: primary operable, locally advanced
and metastatic anthracycline-resistant. Normal breast tissue was
obtained from 6 women who underwent cosmetic surgery. Twenty
primary operable breast cancers were snap-frozen in liquid nitro-
gen during operation and stored at 270°C until use.
Locally advanced breast cancer. Material was obtained from 40
locally advanced breast cancer patients, enrolled in a trial of
high-dose neo-adjuvant chemotherapy consisting of doxorubicin
(90–100 mg/m2) and cyclophosphamide (1 g/m2) on day 1,
followed by 250 µg/m2/day GM-CSF s.c. or i.v. on days 2–11.
Cycles were repeated every 3 weeks (20 patients had 6 cycles, 14
patients 5 cycles, 4 patients 4 cycles, 1 patient 3 cycles and 1
patient 1 cycle). Patients who responded to the treatment under-
went mastectomy and radiotherapy (4,005 cGy in 15 fractions)
(Hoekman et al., 1991). Of 40 patients entered into the study, 17
had adequate material for evaluation before and after neo-adjuvant
chemotherapy. Most tumor tissues before and after neo-adjuvant
chemotherapy were formalin-fixed and paraffin-embedded. Further-
more, for 14 patients only mastectomy material after chemotherapy
was available because they were referred from other institutes and
had only a diagnostic cytologic needle aspiration before chemother-
apy. In 9 cases only tumor material biopsied before chemotherapy
was assessable, because 1 patient received only radiotherapy after
neo-adjuvant chemotherapy, 7 patients had a pathological complete
remission of the primary tumor (3 patients had only a few tumor
cells left in the axillary lymph nodes) and 1 patient did not have
enough tumor cells left to evaluate staining results.
Anthracycline-resistant breast cancer. Tumor tissue was ob-
tained from 10 anthracycline-resistant patients, who participated in
a study of high-dose paclitaxel (3 hr infusion of 250 mg/m2 every 3
weeks, with G-CSF s.c. days 2–19) (Vermorken et al., 1995).
Anthracycline-resistance was defined as progression on an anthra-
cycline-containing regimen, having received at least 2 cycles. All
patients gave informed consent to have skin metastases biopsied
within 2 weeks prior to the first paclitaxel cycle and again directly
after progression on paclitaxel. One patient who did not fulfill the
definition of anthracycline-resistance was, however, entered into
the study because she had received the maximum cumulative dose
of anthracyclines. This patient and 6 others in this group had
sequential sampling before and after paclitaxel therapy. Tissues
were snap-frozen in liquid nitrogen and stored at 270°C until
analysis. Furthermore, paraffin-embedded tumor tissues derived
from the primary tumors of 8 patients in this group were also
collected and analyzed.
Immunohistochemistry
Expression of Pgp, MRP, LRP, p53, Ki-67, topol, topo II-a and
topo II-b was assessed by IHC. Cryostat sections (4 µm) and
cytospin preparations were fixed in acetone or 4% paraformalde-
hyde plus 5% acetic acid (topo II-a) at room temperature.
Formalin-fixed, paraffin-embedded tissue was processed with an
antigen retrieval technique (Shi et al., 1991) in the case of Pgp, p53
and Ki-67 staining. Characteristics of the Abs are summarized in
Table I. Immunohisto/cytochemistry was performed with an avidin-
biotin complex immuno-peroxidase method (Vectastain, Vector,
Burlingame, CA), as described by van der Valk et al. (1990).
Endogenous biotin was blocked with streptavidin (0.1% in PBS)
and d-biotin (0.01% in PBS) (Sigma, St. Louis, MO), or by the
APAAP method (Dakopatts, Copenhagen, Denmark) (Moir et al.,
1983). Slides were incubated with the primaryAbs for 1 hr at room
temperature or overnight at 4°C (LRP56 (paraffin), DO-7). PBS
was used for washing steps, with the exception of LRP56 staining
on formalin-fixed, paraffin-embedded tissues; these slides were
pre-incubated and rinsed in PBS with 0.03% casein (Merck,
Darmstadt, Germany) and 0.05% Tween 20 (Genfarma, Maarssen,
The Netherlands) as described elsewhere (Tacha and McKinney,
1992). For these slides, one extra step was included with mouse-anti-
biotin (Boehringer, Mannheim, Germany), dilution 1:200. For
detection of Pgp in formalin-fixed, paraffin-embedded tissues the
second and third steps of the avidin-biotin complex immunoperoxi-
dase method were repeated. Slides were developed in 0.05%
3,38-diaminobenzidine tetrahydrochloride dihydrate (Sigma) with
0.02% H2O2 in PBS, or in new fuchsine (APAAP). Negative
control slides were run in parallel, omitting the primary antibody or
substituting it with an irrelevant mouse myeloma IgG MAb,
isotype-matched for JSB-1, MRPr1, DO-7 and 6G2.
The cell lines KB3-1, KB-ChR-8-5 and 8226DOX4, described in
detail elsewhere (Linn et al., 1994), served as negative and positive
controls for Pgp staining in all experiments. Other positive controls
included the GLC4/ADR human lung cancer cell line (Zijlstra et
al., 1987) for MRP (Flens et al., 1994), the non-Pgp MDR
SW-1573/2R120 doxorubicin-resistant subline (Scheper et al.,
1993) for LRP56 and the NCI-H322 and NCI-H187 human lung
cancer cell lines for topo I, topo IIa and topo IIb. Normal tonsil
tissue and a colorectal cancer specimen served as positive controls
TABLE I – ANTIBODY CHARACTERISTICS
Ab Directed
against Vendor/donation
Mono/polyclonal
Ab
Host
species
Ab
class Dilution
JSB-1 Pgp (MDR1) Gift of Dr. R.J. Scheper (Amsterdam, The Netherlands) Monoclonal Mouse IgG1 1:50
C219 Pgp (MDR1/3) ITK diagnostics, Uithoorn, The Netherlands Monoclonal Mouse IgG2b 1:100
MRPr11 MRP Gift of Dr. M.J. Flens (Amsterdam, The Netherlands) Monoclonal Rat IgG2a 1:100 (N2)
1:200 (paraffin)
LRP562 LRP Gift of Dr. R.J. Scheper Monoclonal Mouse IgG2b 1:500 (N2)
1:100 (paraffin)
DO-7 p53 Dako, Glostrup, Denmark Monoclonal Mouse IgG2b 1:500
Ki-67 Ki-67 antigen Dako, Glostrup, Denmark Monoclonal Mouse IgG1 1:10 (N2)
Ki-67 Ki-67 antigen Dako, Glostrup, Denmark Polyclonal Rabbit 1:100 (paraffin)
6G23 Topo IIa Gift of Dr. G. Astaldi-Ricotti (Pavia, Italy) Monoclonal Mouse IgG1 1:50
8F83 Topo IIb Gift of Dr. G. Astaldi-Ricotti Monoclonal Mouse IgG2a 1:25
6B53 Topo I Gift of Dr. G. Astaldi-Ricotti Monoclonal Mouse IgG2a 1:25
1Flens et al. (1994).–2Scheper et al. (1993).–3Negri et al. (1992).
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for Ki-67 and p53, respectively. Specimens were independently
scored for each MAb separately by two of us, both blinded to
clinical outcome.
By prior agreement, samples were considered Pgp-positive if
$20% of tumor cells were stained. This cutoff point was based on
previous studies (Linn et al., 1995, 1996; Schneider et al., 1989;
Chan et al., 1991). For LRP56 the following staining pattern was
observed: all tumor cells negative, occasional staining of single
tumor cells (#5%) and a substantial part of tumor cells positive
($10%). Tumor samples were therefore considered positive for
LRP56 if $10% tumor cells were stained, as also described
previously (Izquierdo et al., 1995). For MRP, p53, Ki-67, topo I,
topo IIa and topo IIb, the median expression in the whole group of
breast cancer specimens examined was pre-specified as cutoff
points: 60% for MRP, 1 cell nucleus/slide for p53, 10% for Ki-67,
60% for topo I, 20% for topo IIa and 80% for topo IIb.
Statistics
Linear regression analysis and Spearman’s correlation test were
used to assess correlation between different protein expression
values. Possible correlations between protein expression and
clinico-pathological parameters were assessed by Fisher’s exact
test (two-tailed). For continuous variables, the cutoff point was
either the median value (MRP, p53, Ki-67, topo I, topo IIa and topo
IIb) or dictated by the staining patterns observed (Pgp and LRP).
For some proteins the cutoff point was similar to those used in other
studies (Pgp: Linn et al., 1995; Schneider et al., 1989; Chan et al.,
1991; Linn et al., 1996; LRP: Izquierdo et al., 1995; p53: Allred et
al., 1993; Thor et al., 1992; Ki-67: Railo et al., 1993). The
Wilcoxon test was used to assess changes in protein expression
levels of tumors sampled sequentially before and after chemother-
apy. Survival analysis was performed according to Kaplan and
Meier (1958). For locally advanced cancers, overall survival time
was defined as the time between date of start of neo-adjuvant
chemotherapy and date of last follow-up or death of recurrent
disease. Differences between survival curves were analyzed using
the Mantel-Cox test (Mantel, 1966; Cox, 1972). Tests were carried
out with the BMDP statistical package (Los Angeles, CA).
RESULTS
Patient characteristics are summarized in Table II. Median age in
the locally advanced and metastatic breast cancer patients was
significantly lower than in the group of operable breast cancers
(p 5 0.009).
Concordance between C219 and JSB-1 staining was 76%
(n 5 93; p , 0.0001). In our hands, staining sensitivity was higher
with JSB-1, and because, unlike C219, JSB-1 is MDR1 specific,
Pgp positivity was further defined as staining of $20% tumor cells
with JSB-1.
Formalin-fixed, paraffin-embedded material was unsuitable for
IHC study of topoisomerase expression with the topo MAbs
available. Most tumor material from the locally advanced breast
cancer group was formalin-fixed and paraffin-embedded. There-
fore, information on topoisomerase expression was scarce in this
group (Table III). For many locally advanced breast cancers, frozen
tissue sampling after chemotherapy was impossible, because only
microscopic tumor cells were left, which could not be localized at
macroscopic evaluation.
Protein expression in normal breast tissue
Generally, expression of drug resistance proteins was low or
undetectable in normal breast tissue. Nevertheless, LRP was
expressed in epithelial cells of all samples and in stromal cells of
5/6 samples examined, MRP was found in epithelial cells of 3/6
samples, but not in stroma, and topo IIb was expressed in nucleoli
of virtually all cell types observed.
Differential protein expression in different breast cancer groups
In Table III, the expression of all 8 proteins tested is summarized
for the 3 groups of breast cancer examined. In locally advanced
breast cancer before chemotherapy, Pgp ( p 5 0.0003), p53
( p 5 0.04) and Ki-67 (p 5 0.02) were significantly more often
expressed than in primary operable breast cancer, suggesting that
they may be markers of a more aggressive phenotype.
Remarkably, none of the 9 metastatic, anthracycline-resistant
patients was Pgp-positive.
Interestingly, MRP expression was more frequently observed in
primary operable breast cancer than in more advanced stages of
breast cancer. High frequency of LRP expression was found in all
breast cancer groups examined. Frequency of topo I, topo IIa and
topo IIb expression was similar in primary operable (chemotherapy
naive) and chemotherapy-treated breast cancer groups.
Figures 1 and 2 show typical staining results of all proteins
assessed with IHC.
Predictive value of protein expression for response
Overall clinical response rate in the locally advanced breast
cancer group was 98% (19 complete remissions, 20 partial
remissions, 1 stable disease). Four patients had a pathological
complete remission, and three had a pathological complete remis-
TABLE II – PATIENT CHARACTERISTICS IN DIFFERENT
BREAST CANCER GROUPS
Primary
operable
Locally
advanced
Metastatic
anthracycline-
resistant
N 20 40 10
Median age (range),
years
63 (44–86) 47 (26–63) 53 (43–71)
Clinical stage
I-II 18
III 2 40
IV 10
Axillary lymph node
status
0 12 161 2
1–3 7 7 1
.3 1 15 5
Unknown 22 23
Mean tumor diam-
eter (range),
cm4
2.9 (1.0–8.55) 0 (0–8)1 4.0 (1.5–7.0)
Primary tumor histo-
logical type
Ductal 19 33 9
Lobular 6 1
Colloid 1
Unclassified 16
Differentiation grade
Well-differenti-
ated
2
Moderately differ-
entiated
5 8 2
Poorly differenti-
ated
14 28 8
Unclassified 17 28
Median follow-up
(months)
36 20 52
1Pathologic examination after neo-adjuvant chemotherapy. Clinical
evaluation before neo-adjuvant chemotherapy: N0, 4; N1, 13; N2, 23;
T2, 2, T3, 18, T4, 20 patients.–2One patient had a tumor embolus in the
axilla; one received radiotherapy (mastectomy not performed).–3No
axillary lymph node dissection.–4Diameter at pathologic examination.–
58.5 cm was a pathologic estimation of lymphangitis carcinomatosa.–
6Not enough tumor cells in subclavicular lymph node biopsy for
histologic classification, and pathologic complete remission after
chemotherapy.–7Mucinous carcinoma.–8In 2 cases, not enough tumor
cells were evaluable for differentiation grade.
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sion of the primary tumor, with only a few tumor cells left in
axillary lymph nodes.
None of the 9 metastatic, anthracycline-resistant patients showed
a response on paclitaxel (Vermorken et al., 1995).
Protein expression levels measured before neo-adjuvant chemo-
therapy (Pgp, MRP, LRP, Ki-67 and p53) or before paclitaxel
treatment (Pgp, MRP, LRP, p53, Ki-67, topo I, topo IIa and topo
IIb) had no predictive value for clinical or pathological response
(data not shown). Of the 4 patients with a pathological complete
remission on high-dose doxorubicin/cyclophosphamide, 3 patients
had high Pgp expression ($50%), 2 patients had high p53
expression ($50%) and 2 patients had low Ki-67 expression
(#10%) of the primary tumor. This finding suggests that neither
high Pgp and/or p53 expression, nor low Ki-67 expression, is an
obstacle to tumor cell kill with chemotherapy.
TABLE III – FREQUENCYOF EXPRESSION OF DRUG RESISTANCE PROTEINS IN DIFFERENT BREAST CANCER GROUPS
Protein
Operable
primary
(N 5 20)
Locally advanced (N 5 40)
Metastatic, anthracycline-
resistant (number positive/
number analyzed)
Median expression
(all breast cancers)
% (range)
Before CT
(number positive/
number analyzed)
After CT
(number positive/
number analyzed)
Pgp 22 (10%) 16/25 (64%) 17/30 (57%) 0/9 3 (0–100)
MRP 16 (80%) 2/10 (20%) 9/16 (56%) 1/5 60 (0–100)
LRP 15 (75%) 12/17 (71%) 18/26 (69%) 6/8 65 (0–100)
p53 6 (30%) 17/26 (65%) 16/31 (52%) 1/5 0 (0–90)
Ki-67 7 (35%) 18/25 (72%) 6/31 (19%) 5/8 10 (0–80)
Topoisomerase I 10 (50%) ND1 1/5 3/8 60 (0–100)
Topoisomerase IIa 9 (45%) ND 2/4 3/8 20 (0–80)
Topoisomerase IIb 9 (45%) ND 2/6 6/9 80 (0–100)
1ND, not done.–2Number of cases positive by definition, as described in Material and Methods.
FIGURE 1 – Results of IHC on formalin-fixed, paraffin-embedded
material. Bars: 100 µm. (a) MRP; cytoplasmic and membranous
staining. (b) Pgp (JSB-1); cytoplasmic and membranous staining. (c)
LRP; primarily granular cytoplasmatic staining pattern, and to a lesser
extent membranous. (d) p53; mainly nuclear staining.
FIGURE 2 – Results of IHC on frozen tumor specimens. Bars: 100
µm. (a) Ki-67; nuclear staining was observed in tumor cells, mono-
nuclear infiltrating cells and occasionally in normal breast epithelial
cells. (b) Topoisomerase IIa; staining was generally restricted to tumor
cell nuclei, but in some tumor cells specific cytoplasmic staining was
also observed, with and without nuclear staining. (c) Topoisomerase I;
staining was restricted to epithelial tumor cell nuclei. (d) Topoisomer-
ase IIb; a typical nucleolar staining pattern was expressed in virtually
all cell types present.
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Changes in protein expression after chemotherapy
Locally advanced breast cancer. For 17 patients, tumor material
was available at 2 time points during treatment: a biopsy was taken
before the start of chemotherapy, and tumor specimens were
obtained at the time of mastectomy, after the last chemotherapy
cycle. Protein expression levels before the start of chemotherapy
were compared with the expression values seen after completion of
chemotherapy (4–6 cycles). Figure 3 summarizes results of protein
expression in these samples. After chemotherapy, the percentage of
Pgp-, p53- and LRP-positive tumor cells did not significantly vary.
Interestingly, however, a significant decrease in percentage of
Ki-67-positive tumor cells was observed after chemotherapy
(p 5 0.009), suggesting that tumor cells survive chemotherapy
more readily when out of the cell cycle.
Metastatic anthracycline-resistant breast cancer. No significant
change of expression levels of any of the proteins studied in at least
6 patients (Pgp, LRP, Ki-67 and topo I, IIa and IIb) was observed
comparing samples taken before the start of paclitaxel with
biopsies obtained after progression on paclitaxel. However, a trend
was present for LRP (p 5 0.06) and Ki-67 expression (p 5 0.09)
to decrease after progression on paclitaxel chemotherapy (data not
shown).
Protein expression and clinico-pathological features
We studied the correlations between protein expression and
clinico-pathologic parameters (age, clinical stage, TNM-classifica-
tion, tumor histology and differentiation grade) in 54 untreated
breast cancers (20 operable, 26 locally advanced and 8 primaries of
the anthracycline-resistant group). Pgp expression was more often
observed in advanced stages of breast cancer (stage I, 3/8; IIA, 0/8;
IIB, 0/4; IIIA, 9/17; IIIB, 11/15; p 5 0.004). Furthermore, Pgp
expression was associated with a larger tumor diameter (n 5 53;
p 5 0.04), as reported previously (Linn et al., 1996), suggesting
that Pgp is a marker of an aggressive phenotype.
Ki-67 positivity was associated with younger age (,52 years,
20/26 positive; $52 years, 10/27 positive; p 5 0.005), confirming
its association with a malignant phenotype, as younger age is
related to worse prognosis in breast cancer.
Protein expression and doxorubicin cumulative dose
Patient samples obtained after the administration of .400
mg/m2 doxorubicin cumulative dose (100% dose of epirubicin
equals 66% dose of doxorubicin) were less often Ki-67-positive
than tumor samples taken after administration of #400 mg/m2
(6/28 vs. 35/64 Ki-67-positive; p 5 0.003; linear regression n 5 92;
r 5 20.25; p 5 0.02). No association was found between expres-
sion values of any of the other proteins and cumulative dose of
doxorubicin administered. This result suggests that breast cancer
cells survive doxorubicin-based chemotherapy more readily when
they are in a dormant state.
Co-expression of p53 and Pgp and survival
In the locally advanced breast cancer group, the presence in the
mastectomy specimen of both Pgp-positive and p53-positive tumor
cells was associated with a shorter survival, as reported before in a
smaller series (Pgp 1 /p53 1 patients (n 5 11) with 2-year sur-
vival of 0% vs. the other locally advanced breast cancer patients
(n 5 15) with 2-year survival of 90%; p 5 0.0007) (Linn et al.,
1996).
Relations between expression levels of different proteins in tumors
Pgp expression was confirmed to be associated with nuclear p53
accumulation (n 5 93; r 5 0.34; p , 0.001), as previously ob-
served (Linn et al., 1996).
Ki-67 positivity correlated with topo IIa (n 5 39; r 5 0.42;
p 5 0.008) and less strongly with topo IIb (n 5 41; r 5 0.31;
p 5 0.05), supporting the notion that topo II is involved in
proliferation (Giaccone et al., 1995; Kaufmann et al., 1994;
D’Andrea et al., 1994). A correlation was also found between topo
IIa and topo IIb expression (n 5 39; r 5 0.38; p 5 0.02). Further-
more, an association was present between topo I and both topo
II-isotypes (IIa, n 5 38; r 5 0.33; p 5 0.04; IIb, n 5 38; r 5 0.41;
p 5 0.01). All correlation coefficients were, however, relatively
small, which indicates that these associations are far from being
complete.
DISCUSSION
Breast cancer is an interesting clinical model to investigate
protein expression and changes induced by systemic treatment. In
particular, patients with large tumors are nowadays usually treated
by neo-adjuvant chemotherapy and then by surgery, providing
sufficient tumor material for such studies. Furthermore, the fre-
quent cutaneous localizations of metastases also provides a rela-
tively easy access for biological material.
In a pilot study we had used both IHC and RNase protection
assay to assess expression of MDR1, MRP and topo IIa in patient
samples. However, there was no good concordance between the
two methods, which is probably due to the fact that the RNase
protection assay is a bulk tissue technique. Information on histol-
ogy is lost, while with IHC one can distinguish which cell types
show protein expression. Furthermore, the tumor-to-stroma ratio
varies considerably among samples, as does the protein expression
within stromal components (Linn et al., 1995). These facts make a
bulk tissue technique less suitable for studies on clinical material.
Therefore, we used only IHC in this study.
We studied the expression of several drug resistance markers in
different breast cancer groups and in normal breast tissue. Interest-
ingly, the locally advanced breast cancers, which were more
aggressive than the smaller tumors, had significantly higher
expression of Pgp, p53 and Ki-67. In addition, in chemotherapy-
naive patients, Ki-67 positivity was associated with younger age.
The fact that these proteins have already been identified as markers
of poor prognosis in breast cancer (Verelle et al., 1991; Greenblatt
et al., 1994; Linn et al., 1995, 1996; Allred et al., 1993; Thor et al.,
1992; Railo et al., 1993; Wintzer et al., 1991), as well as in several
other cancer types, supports their association with tumor aggressive-
ness. A significant correlation between increased Pgp expression
and poor prognosis has been observed in osteosarcoma (Baldini et
al., 1995). Interestingly, the presence of Pgp was unrelated to the
response of tumors to chemotherapy. Lack of correlation between
expression of drug resistance proteins and chemotherapy response
was also observed in our study. This suggests that the role of these
markers in tumor progression may be independent from their
putative role in drug resistance (Pinedo and Giaccone, 1995). It is
difficult to determine the exact contribution of these markers to
clinical drug resistance, as most chemotherapeutic regimens con-
sist of a combination of anticancer drugs with at least one drug not
involved in the MDR-phenotype.
Although 16/25 locally advanced breast cancer patients were
Pgp-positive before chemotherapy in our study, Pgp did not have
predictive value regarding pathologic response. This might be in
contrast with results reported by others (Verelle et al., 1991), who
subdivided a group of 17 Pgp-positive, locally advanced breast
cancer patients into 2 subgroups, depending on staining intensity.
The subgroup with strong Pgp-positivity appeared to be associated
with chemoresistance and shorter survival. However, Verelle et al.
(1991) related Pgp expression only to clinical response, and not to
pathologic response. Furthermore, we did not judge staining
intensity, as differences in staining intensity in our series were only
minimal, and easily attributable to experimental variability. Interest-
ingly, some patients who achieved a pathological complete remis-
sion had high Pgp expression and nuclear p53 accumulation in
pretreatment biopsies, indicating that expression of these proteins
is no obstacle to tumor cell kill with a regimen containing
moderately high doses of doxorubicin and cyclophosphamide. In
addition, we did not find a correlation between Pgp expression and
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FIGURE 3 – Changes in protein expression in tumors of locally
advanced breast cancer patients, sampled before and after neo-adjuvant
chemotherapy. While the median tumor diameter decreased from .5
cm (clinical evaluation) to microscopic tumor cell rests (pathologic
examination) after chemotherapy, the expression of Pgp, p53 and LRP
did not consistently vary. In contrast, a significant decrease in the
percentage of Ki-67-positive tumor cells was observed (n 5 16).
Whenever one line represents more than one patient, the number of
patients is indicated next to the corresponding line in the graph.
cumulative doxorubicin dose, in contrast with findings reported in
myeloma (Grogan et al., 1993). In the myeloma study, samples
were obtained for clinical decision making, e.g., at the moment of
therapy failure, and this approach might well have biased the
results, as more malignant tumors may require higher doses of
chemotherapy and may earlier receive a doxorubicin-containing
regimen. However, the observed differences may relate to the
different tumor types studied (breast vs.multiple myeloma).
Goldie and Coldman (1979) hypothesized that tumor cells are
born chemosensitive, but that drug resistance occurs spontaneously
and rapidly, with the likelihood of a resistant cell clone being
present increasing markedly between 104–106 tumor cells (De Vita,
1991). In locally advanced breast cancers, which consist of approxi-
mately 1010–1011 cells, onewould then expect resistant tumor cell clones
to be already present at the moment of diagnosis. While these resistant
cells would only be a minority of the tumor burden before chemother-
apy, theywould be the only tumor cells left after effective chemotherapy.
Based on this hypothesis we studied protein expression in sequential
samples from the same patient before and after chemotherapy. The only
significant change in protein expression we observed was a decrease in
Ki-67. This might indicate the selection of dormant tumor cells by
chemotherapy. Nevertheless, the dormant state of tumor cells itself is
probably not responsible for drug resistance, as demonstrated in the 2
patients with low Ki-67 expression before chemotherapy who achieved
a pathological complete remission. Another hypothesis is that a low
proliferation rate is energetically favorable for survival, and therefore
resistant tumor cellsmight stop cyclingwhenever exposed to chemother-
apy. This is also in line with our finding that in thewhole group of breast
cancers examined, Ki-67 expression correlated inversely with a high
cumulative dose of doxorubicin (.400 mg/m2; p 5 0.003). While in
our series Ki-67 expression did not predict chemotherapy response,
Remvikos et al. (1989) found a correlation between high cell cycle
S-phase fractions in breast cancers and response to a doxorubicin-
containing regimen. The difference with our results may be
explained by the fact that Remvikos et al. (1989) used clinical
response data, instead of pathologic response data, that Ki-67 not
only stains cells in S-phase, but also in late G1, M and G2 phases
(Railo et al., 1993) and that different techniques were used. A few
other groups studied kinetic parameters by means of repeated
fine-needle aspirates and DNA flow cytometry in breast cancer
patients undergoing neo-adjuvant chemotherapy (O’Reilly et al.,
1992; Spyratos et al., 1992). These studies did not report an
increase of tumor cells in the G0-phase after chemotherapy. The
difference with our results may again be due to different tech-
niques, including histology vs. cytology.
A number of strategies have been proposed to kill quiescent
tumor cells; one of them is late intensification treatment (Norton
and Simon, 1977), which appeared to be of benefit in diffuse
aggressive lymphomas (De Vita, 1991). The addition of alkylating
agents, which at high doses can also kill non-proliferating cells,
might be crucial. Another strategy is hormonal-induced expansion
of the growth fraction of a tumor, followed by chemotherapy (Conte
et al., 1985; Fabian et al., 1994). Preliminary results in breast cancer
seemed promising, with an increase in cycling cells after diethylstilbes-
trol administration and an early decrease in proliferating cells after
chemotherapy (Conte et al., 1985).Nine years later, however, a carefully
designed study, including monitoring of estradiol blood levels, failed to
demonstrate a survival benefit of this strategy (Fabian et al., 1994).
Several reasons for the lack of effect were proposed. Patients with a
relatively high baseline growth fraction had only a small absolute
increase in proliferative index after estrogen treatment, which did
not yield improved responses (Fabian et al., 1994). The authors
suggested restricting future efforts in hormonal recruitment to
patients with a low baseline proliferative index. Another assump-
tion for the lack of success of hormonal recruitment was a
supposedly high MDR1 expression level in locally advanced breast
cancer before chemotherapy (Verelle et al., 1991).
We also studied protein expression in a small group of anthracy-
cline-resistant, metastatic breast cancer patients undergoing pacli-
taxel treatment. In this group we saw no responders to paclitaxel.
Remarkably, none of the 9 anthracycline-resistant patients was
Pgp-positive. Furthermore, topo IIa expression was comparable to
that in the primary operable breast cancer group, rendering
decreased topo IIa expression also an unlikely explanation for
anthracycline resistance in this group. However, with the technique
used we cannot exclude decreased topo IIa activity or an altered
gene as playing a role in anthracycline resistance.
We found a correlation between topo IIa and b in breast cancer,
albeit weaker than reported for AML (Kaufmann et al., 1994), and
stronger than observed in lung cancer (Giaccone et al., 1995),
indicating possible differences between tumor types. In the AML
study, topo IIa and topo IIb content appeared relatively constant
over time in 20 paired samples from AML patients obtained at
diagnosis and relapse (Kaufmann et al., 1994). In line with these
results, we found relatively constant topo IIa and topo IIb
expression values in different breast cancer groups, and no
consistent change in expression in 7 sequentially sampled meta-
static breast cancer patients undergoing paclitaxel treatment. As in
our study, a marked cell-to-cell heterogeneity of topo IIa expres-
sion was observed in AML, using immunocytochemistry. In our
study, Ki-67 positivity correlated with topo IIa ( p 5 0.008), and
less strongly with topo IIb expression (p 5 0.05), which corre-
sponds with results reported by others, who studied Ki-67, topo IIa
and topo IIb expression in several human tumors (D’Andrea et al.,
1994). For AML (Kaufmann et al., 1994) and lung cancer
(Giaccone et al., 1995), topo IIa, but not topo IIb, has been
suggested to serve as a proliferation marker.
Topo I expression was virtually undetectable in normal breast
tissue, while it was expressed in 50% of primary operable breast
cancers, which may explain some of the activity of topo I inhibitors
in breast cancer observed during phase I trials (Burris et al., 1992).
Furthermore, a correlation between topo I and both topo II isoforms
was found in breast cancer, which might be of interest for future
treatment designs, including topo I and topo II inhibitors.
In conclusion, it is feasible to serially study tumor resistance
markers in breast cancer patients undergoing neo-adjuvant chemo-
therapy. Our results suggest that only a quiescent tumor cell status,
as assessed with Ki-67, but not Pgp, LRP or p53 expression, might
play some role in drug resistance of breast cancer. Independent of
their putative role in drug resistance, Ki-67, Pgp and p53 may be
involved in tumor progression. None of the markers studied
reliably predicted tumor response. New treatment strategies di-
rected against those quiescent tumor cells, that are not killed by the
available drugs, are awaited. High-dose chemotherapy is being
tested and may provide a valid approach in patients with small
tumor burden. Surgery after neo-adjuvant chemotherapy remains
definitely recommended for optimal local control in locally ad-
vanced breast cancer patients.
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